Biontech Stock

Biontech EBIT

The EBIT of Biontech (BNTX) as of Jul 26, 2026 is -623.87 M EUR. In the previous year, EBIT was -1.31 B EUR — a change of -52.53% (higher).

EBIT

-623.87 MEUR

YoY

-52.53%

Last updated:

In 2026, Biontech's EBIT was -623.87 M EUR, a -52.53% increase from the -1.31 B EUR EBIT recorded in the previous year.

The Biontech EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT (B EUR)
Date
EBIT (B EUR)
Jan 1, 2024
-1.31 base
Jan 1, 2025
-0.62 base
Jan 1, 2026 (e)
-1.20 base
Jan 1, 2027 (e)
-1.36 base
Jan 1, 2028 (e)
-0.82 base
Jan 1, 2029 (e)
-0.77 base
Jan 1, 2030 (e)
-0.54 base
Jan 1, 2031 (e)
0.00 base
YEAREBIT (B EUR)
2031 est -
2030 est -0.54
2029 est -0.77
2028 est -0.82
2027 est -1.36
2026 est -1.20
2025 -0.62
2024 -1.31
2023 0.69
2022 12.64
2021 15.28
2020 -0.08
2019 -0.18
2018 -0.05
2017 -0.06
Access this data via the Eulerpool API

Biontech Revenue

Biontech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2024
2.75 B EUR
-1.31 B EUR
-665.30 M EUR
Jan 1, 2025
2.76 B EUR
-623.87 M EUR
-1.09 B EUR
Jan 1, 2026 (e)
2.17 B EUR
-1.20 B EUR
-1.11 B EUR
Jan 1, 2027 (e)
2.23 B EUR
-1.36 B EUR
-1.06 B EUR
Jan 1, 2028 (e)
3.06 B EUR
-815.06 M EUR
-33.32 M EUR
Jan 1, 2029 (e)
2.83 B EUR
-768.51 M EUR
0.00 EUR
Jan 1, 2030 (e)
3.40 B EUR
-541.95 M EUR
-380.12 M EUR
Jan 1, 2031 (e)
4.84 B EUR
0.00 EUR
601.23 M EUR

Biontech Margins

Biontech stock margins

The Biontech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Biontech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Biontech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2024
80.32 %
-47.77 %
-24.18 %
Jan 1, 2025
77.64 %
-22.63 %
-39.59 %
Jan 1, 2026 (e)
77.64 %
-55.49 %
-51.11 %
Jan 1, 2027 (e)
77.64 %
-60.90 %
-47.70 %
Jan 1, 2028 (e)
77.64 %
-26.63 %
-1.09 %
Jan 1, 2029 (e)
77.64 %
-27.18 %
0.00 %
Jan 1, 2030 (e)
77.64 %
-15.93 %
-11.17 %
Jan 1, 2031 (e)
77.64 %
0.00 %
12.42 %

Biontech Stock analysis

What does Biontech do? BioNTech SE is a German biotech company specializing in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2008 by Ugur Sahin and Özlem Türeci and is headquartered in Mainz. History: BioNTech was established to develop novel treatment options for cancer patients. Originally started as a pure research company, the company has since evolved into a global leader in mRNA-based therapeutics. In recent years, BioNTech has entered into numerous collaborations and partnerships with renowned pharmaceutical companies and other research institutions to strengthen its innovative power and competitiveness. Business model: BioNTech's business model involves developing novel mRNA-based therapeutics for the treatment of cancer and other serious diseases. The company relies on close collaboration with other research institutions and pharmaceutical companies to leverage the latest scientific knowledge and technologies. BioNTech aims to bring its therapeutics to market as quickly as possible to enable more effective treatment for patients worldwide. Divisions: BioNTech is divided into various divisions to optimize its research activities. One of the most important divisions is cancer research, in which the company specifically seeks new treatment options for various types of cancer. BioNTech focuses on the development of personalized cancer immunotherapy tailored to the individual needs of each patient. In this context, the company works closely with other researchers and oncologists to achieve the best possible outcomes. Another important area of BioNTech is vaccine development. The company uses mRNA technology to rapidly and effectively develop vaccines against various infectious diseases. In 2020, BioNTech, together with the US pharmaceutical company Pfizer, brought the first mRNA vaccine against COVID-19 to the market, which has high efficacy and safety. This technology enables rapid response to new pathogens and targeted vaccine development. Products: BioNTech offers a variety of therapeutics and vaccines based on mRNA technology. One of the company's most important products is the mRNA vaccine against COVID-19, which is in use worldwide. In addition, BioNTech develops personalized cancer immunotherapies tailored to the individual characteristics of patients' tumors. Another product of BioNTech is mRNA immunotherapies that can be used for various autoimmune diseases. Conclusion: BioNTech is an innovative biotech company specializing in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. With its business model that relies on collaborations and partnerships, the company is able to rapidly and effectively respond to new challenges while staying scientifically up to date. BioNTech has brought a variety of products to the market in a short period of time that have high efficacy and safety, thereby helping patients worldwide. Answer: BioNTech is a German biotech company that specializes in the development of mRNA-based therapeutics for the treatment of cancer and other serious diseases. Biontech is one of the most popular companies on Eulerpool.

EBIT Details

Analyzing Biontech's EBIT

Biontech's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of Biontech's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

Biontech's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in Biontech’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about Biontech stock

EBIT of Biontech is -623.87 M EUR in 2026.

The sales revenue is important for evaluating a stock.

EBIT is an acronym for "Earnings Before Interest and Tax" and represents a company's gross profit before taxes and interest are deducted. The EBIT amount is often used as a metric to evaluate a company.

History

The EBIT was originally introduced in the 1940s when the US Internal Revenue Service (IRS) passed a new tax law. This law required companies to calculate their profit before deducting taxes and interest on loans (or "interest and taxes"). Since then, the EBIT has been used as one of the key financial indicators in evaluating a company.

Usage

The EBIT can be used to assess a company by comparing its financial results to a benchmark or a comparative value. The EBIT is also used to determine how much the company's shareholders will receive from its operating income.

Calculation

EBIT is calculated by deducting taxes and interest on loans from the company's net profit. This amount can be calculated in various ways, but the most common method is as follows:

EBIT = Net profit + interest and taxes

Example: Eulerpool: Your source for quantitative stock data At Eulerpool, we are dedicated to providing you with comprehensive and accurate stock information. Our website offers a wide range of tools and features, including charts, stock lists, and more. Whether you are an experienced investor or just starting out, our platform is designed to meet your needs. With our in-depth analytics and algorithms, you can make informed decisions and stay ahead of the market. Explore our extensive collection of stocks, track their performance, and access real-time data. With Eulerpool, you can easily navigate the world of finance and monitor the stocks that matter to you. Join our community today and gain valuable insights into the world of stocks and investments. Sign up for free and discover the power of Eulerpool. Stay informed. Stay ahead. Eulerpool - your trusted partner in stock data.
Net profit of XYZ Co. = $1,000,000
Interest and taxes = $ 500,000
EBIT of XYZ Co. = $1,500,000

Application

The EBIT value is often used to determine and evaluate the financial stability of a company. The EBIT value can also be used to determine how much money a company can spend on investments or dividends.

Use of EBIT in stock investment

Investors use EBIT to determine if a stock is over- or undervalued. If a company has a high EBIT value, it may indicate that its stock is overvalued, as the profit it generates could be lower than what it would generate with a different stock.

Advantages of EBIT

EBIT is a helpful measure for determining the financial stability of a company. There are several advantages associated with using EBIT, such as:
- EBIT eliminates the impact of financing on the company's earnings.
- It is a useful measure for determining the profits that a company can distribute to its shareholders.
- It can be used to determine whether a stock is overvalued or undervalued.

Disadvantages of EBIT

There are also some disadvantages to using EBIT, such as:
- EBIT cannot be used as the sole measure to evaluate a company as it does not reflect the overall profit of the company.
- EBIT can be influenced by unforeseen events such as a tax increase.
- EBIT is not always a reliable indicator of a company's future profit development.

Conclusion

The EBIT is an important measure used to evaluate a company. It can be used to determine how much money a company can generate from its operational results and whether a stock is overvalued or undervalued. However, the EBIT also has some disadvantages as it does not reflect the overall profitability of a company and can be influenced by unforeseen events. Therefore, it is important to consider the EBIT in conjunction with other financial indicators to obtain a complete picture of the company.

Access this data via the Eulerpool API

Income Statement — Biontech

All Key Metrics — Biontech